Molecular pathology selected abstracts
January 2026—Two studies investigated the use of DNA methylation patterns and sex-specific gene expression in neuroendocrine neoplasms (NEN) and Alzheimer disease, respectively.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, December 1, 2026, 1 PM-2 PM ET
Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.
Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Abstracts
Anatomic pathology selected abstracts
December 2025—Unusual morphologic patterns of breast carcinoma can raise diagnostic consideration for metastasis or special breast cancer subtypes and, thereby, impact clinical management and treatment. The authors conducted a study in which they described rare invasive breast cancers that mimic serous carcinoma of the gynecologic tract (serous-like breast carcinomas, SLBC) and characterized their clinicopathologic, immunophenotypic, and genetic features. The patients evaluated in the study were female (n = 15; median age, 49 years) and did not have a history of gynecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple negative (n = 10) or HER2 positive (n = 2) and grade 2 or 3, while some were estrogen receptor low positive/HER2 negative and low grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10 of 10).
Molecular pathology selected abstracts
December 2025—Two studies explore the evolution of Mycobacterium tuberculosis and the significance of GATA1 mutations in children with Down syndrome. The first study reveals diversity in virulence gene expression across Mtb clinical isolates, with variants in the regulator whiB6 linked to decreased expression of virulence factors and increased transmission of drug-resistant strains. The second study investigates the clinical significance of GATA1 mutations in neonates with Down syndrome, finding that the presence of GATA1s mutations at birth is a strong predictor of myeloid leukemia associated with Down syndrome (ML-DS).
Clinical pathology selected abstracts
November 2025—A study analyzed data from 6,068 individuals who received a commercial blood-based CRC screening test between May 2022 and September 2024. The study found that 49% of individuals with an abnormal result received a follow-up colonoscopy within six months, with a mean time of 66.4 days.
Anatomic pathology selected abstracts
November 2025—A HER2-low–focused IHC scoring system was validated by nine breast pathologists using digitized images of HER2 IHC slides. The system demonstrated high performance metrics, including accuracy, sensitivity, and specificity, across two data sets, validating its effectiveness.
Molecular pathology selected abstracts
November 2025—A study of four laboratories’ experiences with subclassifying variants of uncertain significance (VUS) found that variants were more likely to be reclassified as benign than pathogenic. The VUS-high subclass had the highest percentage of reclassifications, but represented a smaller proportion of total VUS classifications.
Clinical pathology selected abstracts
October 2025—Whole genome sequencing is being evaluated in newborn screening to increase the diagnosis and treatment of rare clinical conditions. Such screening raises ethical questions about which results to report and the impact of those results on parents and their children. It is important to focus on societal norms when designing whole genome sequencing–newborn screening (WGS-NBS) to make sure people accept the testing and minimize patient harm. Although parents value the fact that WGS-NBS can lead to early diagnosis and treatment of various conditions, they recognize that results may cause psychological distress, eliminate children’s autonomy, raise data-storage and privacy concerns, and lead to uncertainty regarding adult-onset medical conditions. The public, in general, supports WGS-NBS for clinically actionable childhood-onset conditions, with the caveats that health professionals are trained to interpret such results and genetic counseling is available.
Anatomic pathology selected abstracts
October 2025—Crystal-storing histiocytosis is a rare disorder in which crystals accumulate in the cytoplasm of histiocytes. It is usually associated with a lymphoplasmacytic neoplasm. Cutaneous crystal-storing histiocytosis (CSH) is extraordinarily rare and limited to case reports in the literature. The authors reported on two cases of CSH with cutaneous involvement. Case one was a 65-year-old male with a four-month history of a pruritic eruption that started as a solitary pink to skin-colored indurated plaque on the anterior neck before progressing to involve the whole neck, chest wall, and face.
Molecular pathology selected abstracts
October 2025—GATA2 deficiency is a rare inherited condition that disrupts the normal development of blood and immune cells. People born with this genetic disorder may experience low blood counts, frequent infections, or such problems as lymphedema and hearing loss. The most serious long-term risk is development of myelodysplastic syndrome (MDS), a bone marrow disorder that can progress to leukemia. The authors conducted a large study in which they followed 218 people with confirmed GATA2 mutations to understand when and how MDS develops. In this cohort, symptoms of GATA2 deficiency were present in 205 of the participants, of whom 187 (91.2 percent) had MDS.
Pathology informatics selected abstracts
October 2025—Large language models are becoming commonplace for personal and business use. The health care community is leveraging large language models (LLMs) for various purposes. Researchers at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, have successfully used open-source LLMs to extract critical medical data from pathology reports. They conducted a study that demonstrated how LLMs can transform unstructured clinical text into structured pathology data. While pathology reports are rich in information about tumor type, size, and stage, their narrative format makes automated data extraction difficult.